Paragon 28 Launches JAWS™ Great White Staple System Further Expanding its Nitinol Staple Offering
14 Novembre 2023 - 2:00PM
Business Wire
Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch
of its JAWS™ Great White Staple System which was developed to
provide for increased strength and stability of the osteotomy or
fusion site when compared to traditional staple systems. The
staples feature an ultra-low-profile bridge with increased surface
area to enhance stability while minimizing soft tissue irritation.
The newly designed staple has 400 times the fatigue life compared
to a competitive nitinol staple subjected to the same load
parameters.1 The shoulders of the staple work in conjunction with
the inserter allowing the staple to be fully seated prior to
compression activation limiting the need to tamp. The staples were
designed to provide a uniform compression profile across the
osteotomy and provide a 169% increased compressive force when
compared to the average of a competitive marketing leading
two-prong, nitinol staple.1
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231114327913/en/
JAWS Great White Staple System (including
12, 15-, 18-, 20-, and 25-mm Staples) (Photo: Business Wire)
Paragon 28’s CEO, Albert DaCosta, commented, “We are excited to
continue to expand our JAWS™ staple offering allowing surgeons to
address the complexities of midfoot and hindfoot reconstruction.
Our development team has designed implants which provide for
greater fatigue resistance and increased compression when compared
to market leading nitinol staple systems. We look forward to
increasing our market position in the midfoot and hindfoot segments
with this exciting offering.”
The addition of the JAWS™ Great White Staple System bolsters
Paragon 28’s hindfoot solutions product offering, which includes
the Gorilla® Ankle Fracture Plating System, APEX 3D™ Total Ankle
Replacement, Silverback™ Ankle Fusion Plating System, Phantom® TTC
Nail System, and Phantom® ActivCore™ Nail System. With this
comprehensive portfolio, Paragon 28® provides its customers with
innovative ankle solutions for trauma, arthritis, and limb
salvage.
About Paragon 28, Inc.
Based in Englewood, CO., Paragon 28, is a leading medical device
company exclusively focused on the foot and ankle orthopedic market
and is dedicated to improving patient lives. From the onset,
Paragon 28® has provided innovative orthopedic solutions,
procedural approaches and instrumentation that cover a wide range
of foot and ankle ailments including fracture fixation, forefoot,
ankle, progressive collapsing foot deformity (PCFD) or flatfoot,
Charcot foot and orthobiologics. The company designs products with
both the patient and surgeon in mind, with the goal of improving
outcomes, reducing ailment recurrence and complication rates, and
making the procedures simpler, consistent, and reproducible.
Forward Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to: Paragon 28’s potential to shape a better future
for foot and ankle patients. You are cautioned not to place undue
reliance on these forward-looking statements. Forward-looking
statements are only predictions based on our current expectations,
estimates, and assumptions, valid only as of the date they are
made, and subject to risks and uncertainties, some of which we are
not currently aware. Forward‐looking statements should not be read
as a guarantee of future performance or results and may not
necessarily be accurate indications of the times at, or by, which
such performance or results will be achieved. These forward‐looking
statements are based on Paragon 28’s current expectations and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward‐looking statements as a result of these
risks and uncertainties. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Paragon 28’s business in general, see Paragon 28’s
current and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2022 and its Quarterly Reports on Form
10-Q, as updated periodically with its other filings with the SEC.
These forward-looking statements are made as of the date of this
press release, and Paragon 28 assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
Disclaimer
Nothing in this material is intended to provide specific medical
advice or to take the place of written law or regulations.
1. Internal Test Data on File
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231114327913/en/
Investor Contact Matthew Brinckman Senior Vice President,
Strategy and Investor Relations Phone: (720) 912-1332
mbrinckman@paragon28.com
Paragon 28 (NYSE:FNA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Paragon 28 (NYSE:FNA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024